These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 22154380)

  • 1. Frequency of mold and pollen mixing in allergen immunotherapy prescriptions within a large health care system, 1990-2010.
    Gada S; Haymore B; McCoy L; Kosisky S; Nelson M
    J Allergy Clin Immunol; 2012 Apr; 129(4):1151-3. PubMed ID: 22154380
    [No Abstract]   [Full Text] [Related]  

  • 2. Anaphylaxis caused by allergen sublingual immunotherapy?
    André C; Fadel R
    Allergy; 2007 Oct; 62(10):1220-1. PubMed ID: 17845597
    [No Abstract]   [Full Text] [Related]  

  • 3. Guidelines for using pollen cross-reactivity in formulating allergen immunotherapy.
    Weber RW
    J Allergy Clin Immunol; 2008 Jul; 122(1):219-21. PubMed ID: 18602577
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetic engineering of pollen allergens for hayfever immunotherapy.
    Bhalla PL
    Expert Rev Vaccines; 2003 Feb; 2(1):75-84. PubMed ID: 12901599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study.
    Senti G; von Moos S; Tay F; Graf N; Sonderegger T; Johansen P; Kündig TM
    J Allergy Clin Immunol; 2012 Jan; 129(1):128-35. PubMed ID: 21996342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrial fibrillation associated with anaphylaxis during venom and pollen immunotherapy.
    Patel SC; Detjen PF
    Ann Allergy Asthma Immunol; 2002 Aug; 89(2):209-11. PubMed ID: 12197580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allergen immunotherapy practice in the United States: guidelines, measures, and outcomes.
    Cox L; Esch RE; Corbett M; Hankin C; Nelson M; Plunkett G
    Ann Allergy Asthma Immunol; 2011 Oct; 107(4):289-99; quiz 300. PubMed ID: 21962088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
    Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
    J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic effects of encapsulated short ragweed extract: a potent new agent for oral immunotherapy.
    Litwin A; Flanagan M; Entis G; Gottschlich G; Esch R; Gartside P; Michael JG
    Ann Allergy Asthma Immunol; 1996 Aug; 77(2):132-8. PubMed ID: 8760779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
    Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
    Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy.
    Van Overtvelt L; Baron-Bodo V; Horiot S; Moussu H; Ricarte C; Horak F; Zieglmayer P; Zieglmayer R; Montagut A; Galvain S; de Beaumont O; Le Gall M; Moingeon P
    Allergy; 2011 Dec; 66(12):1530-7. PubMed ID: 21883279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration regimens for sublingual immunotherapy to pollen allergens: what do we know?
    Lombardi C; Incorvaia C; Braga M; Senna G; Canonica GW; Passalacqua G
    Allergy; 2009 Jun; 64(6):849-54. PubMed ID: 19392995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of immunotherapy on the pathophysiology of ragweed pollen allergy.
    Ford SA; Baroody FM; Naclerio RM
    Rhinol Suppl; 1992; 14():52-6. PubMed ID: 1389403
    [No Abstract]   [Full Text] [Related]  

  • 14. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study.
    Pfaar O; Barth C; Jaschke C; Hörmann K; Klimek L
    Int Arch Allergy Immunol; 2011; 154(4):336-44. PubMed ID: 20975285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of pediatric eosinophilic esophagitis diagnosis to pollen and mold counts.
    Schlegel CR; Quintanilla NM; Olive AP; Minard CG; Davis CM
    Ann Allergy Asthma Immunol; 2014 Sep; 113(3):321-2. PubMed ID: 24996994
    [No Abstract]   [Full Text] [Related]  

  • 16. Injectable immunotherapy: recommendations for safe allergen vial preparation in the office setting.
    Lay PC
    Curr Opin Otolaryngol Head Neck Surg; 2009 Jun; 17(3):223-5. PubMed ID: 19395969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral reactions to sublingual immunotherapy: a bioptic study.
    Marcucci F; Sensi L; Incorvaia C; Di Cara G; Moingeon P; Frati F
    Allergy; 2007 Dec; 62(12):1475-7. PubMed ID: 17983387
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of the risk of infection associated with subcutaneous allergen immunotherapy: American Academy of Allergy, Asthma, and Immunology and American College of Allergy, Asthma, and Immunology National Surveillance Study on Allergen Immunotherapy, 2014-2015.
    Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI
    Ann Allergy Asthma Immunol; 2017 Apr; 118(4):511-512. PubMed ID: 28259390
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety of sublingual grass pollen immunotherapy after anaphylaxis.
    Nichani JR; de Carpentier J
    J Laryngol Otol; 2009 Jun; 123(6):683-4. PubMed ID: 18501039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allergen immunotherapy practice parameter update.
    Smith CS
    J Ky Med Assoc; 2004 Feb; 102(2):53-6. PubMed ID: 15004935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.